RespireRx Pharmaceuticals Inc (CE) (RSPI) News

"I have not read"

Spoken like a true non-INVESTOR

Good luck to all of us who have invested here!

I have not read "all the publications and past press and commentary related to their prime compounds in development" but you didn't respond to the specifics of my post. I have looked at the latest filing and I know how to use clinicaltrials.gov.
1. Only one clinical trial of cx-1739 was conducted. It was in 2016 and the Company didn't make any changes after the Quality Control Review. Hence "Status Unknown".

2. Please show the purported KRM-11-81 results that show it to be superior to all in preclinical metrics.

Again I just look at valuation comparables considering market size, implications and fully diluted estimated share structure. As you mentioned irrational momentum is typical on the otc.

Entering human clinical trials is a big deal for any drug company, entering multiple trials is really big deal. It is only logical higher level pharma and biotech investors would have an interest here. Hopefully we hear about funding and opening a floodgate of communication sooner than later.

I’ve actually read all the publications and past press and commentary related to their prime compounds in development. I suspect you have not.

The gabakine preclinical success thus far published has shown to be superior. Shareholders do not have any color on the success in tier 3 NIH but hiring a consultant firm is indicative.

All the due diligence is out there. Read the filings, the PR, the publications.

" Hence the success of CX-1739 in prior clinical trials yielding a now government funded phase 2."
Only one trial of cx-1739 was submitted to clinicaltrials.gov. It's from 2016, they enrolled 18 individuals and it shows as status "unknown".
https://clinicaltrials.gov/study/NCT02735629?intr=cx-1739&rank=1&tab=history&a=3#version-content-panel

"Also the NIH preclinicals for KRM-ll-81. It is not every day that a preclinical compound is this successful and results show it to be superior to all in preclinical metrics. "
That's funny. Only 10 days ago you commented on the absence of color, now it's "successful" and "superior":
"Probably an early 2025 item on grant status based upon NIH online listed review process, but would love to hear some color as to how successful has KRM-ll-81 been in the NIH preclinicals."

"and now a reputable consultant group going to handle grant funding management".
Didn't they have to delay the submission date for a month. Was the new submission date (~8/28) met?

Your estimated return on investment would be huge, my estimated return on investment, massive. My estimate takes into account likely irrational valuation due to momentum investors who would jack up value way past reality. We all have seen this.

Opti shark attack

Unique more in that the pipeline in my opinion has been and currently is extremely undervalued.

The DOD and NIH news and upcoming clinical efforts only solidifies those who had been accumulating long and continued to do so after the DOD announcement. Logic suggests the silence would relate to a financing deal of some level which they stated in 8-k was how they would rectify this EM situation. The tidying up of language on the prefferred is also indicative of money at the door. What shape or form this all takes will be most interesting. I could see a BP take on an equity position as part of a round of financing. I could also see a spin out of some assets similar to OSA program. Their window of opportunity to grow awareness and really become something special with these upcoming clinical trials is fast approaching.

Imagine if they secure some level of financing to support both the DOD phase 2 and NIH epilepsy phase 1. Update all website information, update on all publications and patents, update on collaborations, update on OSA program status and what is holding that up, discuss potential milestones and the lead in's to ADHD, PAIN, orphan indications. Really could be quite a story to tell and help this company sustain 50+/- million valuation that would give all the flexibility in the world to capitalize on acquiring additional resources or exploiting their platforms into additional collaborations/clinical efforts. The ingredients are there, just waiting for the cooks in the kitchen...

Well, LT, one thing I believe we agree on is that RSPI is unique in any point in the history of biotech. Is RSPI's behavior based on their belief that all their platforms will propel the company from a 1 million to multibillion valuation justifies their silence for now? We will see if that occurs, but I am willing to wait for that prospect.

No problem. Agree to disagree is what made this country great.

Obviously I have strong beliefs in the science as well as you do. I've done my due diligence and think the potential is truly amazing to address some large unmet needs and definitely has been way undervalued. As an investor however, one must acknowledge the complete lack of filings/updates/communication as unacceptable. The strength of the assets and the position with multiple heading into human clinicals far outweighs here but reality is the best biotechs and pharmas out there have both a strong science side and business savvy that end up extracting the most potential from one another...

I00% correct in my view

Whatever. Regardless, I am sure grateful that it appears I will have some of the pie when these scientists come out of the darkness and reveal all that has and is doing on. Just shows that we can both look at the same facts nd come to entirely different conclusions.

I think most investors would disagree with this sentiment.

A publicly traded company has a fiduciary duty to its stakeholders, there are no excuses for lacking in this duty. This includes shareholders, debt holders, preferred, vendors, collaborators, etc, etc. If control individuals were sufficiently well off, then they should have financed these projects without the need to be publicly traded entity and seek investment monies.

Even the best science will be mired in quicksand without supporting business/financial side of it all.

"yet there should be no excuses for this lack of information" On the contrary, the folks in control at RSPI have science mindset and if all currently have sufficiently confrontable personal income, the science comes first. For me over the last 50 years, I have driven my wife crazy where my decisions have principally been science and not money oriented. That position has been successful: we are comfortable, but not wealthy by any means. There are projects I started years ago where my family question these decisions that turned to be a nice income supplement over SS and best of all, I am still about the science; the foundations for me were established many years ago. And most importantly, I am still having a blast! So, guys, be patient. I am convinced the rewards will come when they are ready. All that I have seen indicates it will happen.

What is bid and ask?

"I think a successful clinical trial result would be more indicative of that than some funding"

Agreed. Hence the success of CX-1739 in prior clinical trials yielding a now government funded phase 2. They also have this compound or similar slated for ADHD at some point. Clinical success, conducted by very reputable individuals and institutions led it to this point.

Also the NIH preclinicals for KRM-ll-81. It is not every day that a preclinical compound is this successful and results show it to be superior to all in preclinical metrics. Human translation is never a guarantee in drug development, but dang the odds are much much higher and conducted with the NIH and now a reputable consultant group going to handle grant funding management. I think this preclinical success especially for epilepsy would intrigue many a biotech or pharma investor! It does me.

Alas though, this still has the appearance of clowning around on the OTC. The progress of these platforms to this point with minimal resources is commendable, there is significant potential, yet there should be no excuses for this lack of information, it is indeed a failure on the part of management and whatever consul they are given and does a disservice to the assets. Current status should dissappoint all stakeholders.

"Good thing is that the "future" always comes around."
That's historically true, but the pipeline has yet to produce a marketable product (or a Phase 3 clinical trial if I'm not mistaken) and the Company was incorporated 37 years ago. I know that the drug development process can be time consuming, but.....

"DOD funded phase 2 SCI, NIH grant funding for epilepsy likely, OSA program poised in Australia... All suggests the future is now."
Do they? I think a successful clinical trial result would be more indicative of that than some funding and posturing.

LT.
The last five years ampakine research all over the world has exploded. Some of the early publications on ampakines out of UCI have been referenced over 250 times! Incredible. Do any of you really think countries such as China will respect US patents and do their own clinical trials? Then there is the DOD, who I suspect is clinical-trial testing CX929. If all these ampakines showing preclinical success are also successful in the clinic, under the FDA or not, the benefit for so many neurological diseases will have enormous economic benefit.

I like it.

But honestly I am targeting more nickel, dime, quarter for near, medium, long term.. It is the otc however and have seen much crazier valuations on much much less.

"The pipeline has been a figment of the future since the Company was created."

Good thing is that the "future" always comes around.

DOD funded phase 2 SCI, NIH grant funding for epilepsy likely, OSA program poised in Australia... All suggests the future is now.

Why are you folks are thinking in pennies? I am thinking in dollars!

CX546: Has been classified as a prototype drug. “Prototypes the first developed drugs within the class and are used as a reference to which all other drugs are compared.”
Impaired learning and memory generated by hyperthyroidism is rescued by restoration of AMPA and NMDA receptors function
Neurobiology of disease PubMed ID: 35777536 Sept 2022
Wei Zhu 1 , Fengming Wu 1 , Jiong Li, Lianghui Meng, Wenjun Zhang, Huijie Zhang, Shuhan Cha, Jifeng Zhang * , Guoqing Guo * Department of Anatomy, Neuroscience Laboratory for Cognitive and Developmental Disorders, Medical College of Jinan University, Guangzhou 510630, China

ABSTRACT Hyperthyroidism has been identified as a risk factor for cognitive disorders. The hippocampus is a key brain region associated with cognitive function, among which excitatory synapse transmission plays an important role in the process of learning and memory. However, the mechanism by which hyperthyroidism leads to cognitive dysfunction through a synaptic mechanism remains unknown. We investigated the synaptic mechanisms in the effects of hyperthyroidism in an animal model that involved repeated injection of triiodothyronine (T3). These mice displayed impaired learning and memory in the Novel object recognition test, Y-maze test, and Morris Water Maze test, as well as elevated anxiety in the elevated plus maze. Mature dendritic spines in the hippo campal CA1 region of hyperthyroid mice were significantly decreased, accompanied by decreased level of AMPA and NMDA-type glutamate receptors in the hippocampus. In primary cultured hippocampal neurons, levels of AMPA- and NMDA-type glutamate receptors also decreased and whole-cell patch-clamp recording revealed that excitatory synaptic function was obviously attenuated after T3 treatment. Notably, pharmacological activation of AMPAR or NMDAR by intraperitoneal injection of CX546, an AMPAR agonist, or NMDA, an NMDAR agonist can restore excitatory synaptic function and corrected impaired learning and memory deficit in hyperthyroid mice. Together, our findings uncovered a previously unrecognized AMPAR and NMDAR-dependent mechanism involved in regulating hippocampal excitatory synaptic transmission and learning and memory disorders in hyperthyroidism.

Lol nothing to be cute about u will see them at 003-004 soon enough.

You got cute andlscoffed at CYBL saying "They got 33m in assets also 33m in lability’s lol."
At 6/30/24 they had $52M in Assets and $32 M in liabilities.
Meanwhile RSPI's latest filing as of 9/30/23 showed them having $108,664 in Assets and $12,405,118 in Liabilities.

Your inability to read a financial statement led you to make a comparison that was both false and against your own interests. Even if it were true it would have shown CYBL to have a far healthier Balance Sheet than this Company has.

Of course your fallback position is "It doesn't matter" but it does. IF, and it's a BIG IF,\ the CFO is being truthful when he says that the debt due to the Company's Auditors is the reason the filings haven't been made, the lack of cash ($6,362) at 9/30/23 is a failure of management and only a fool would be loling at another Company's working capital position when it is far better than RSPI's.

Any sane investor that looks at $.0013 and Expert Market and filings that are overdue by a year shouldn't need to know anything else. The pipeline has been a figment of the future since the Company was created.

Enjoy your denial Menace.

This is a bio tech company what are u trying to insinuate by saying we have 12m in liability’s? Know the market before being opinionated. The majority of bio tech start ups have negative balance sheet. Ur not investing in their current financials, u invest in the potential likelihood of their compounds attracting institutional partnership or assets hitting the market. Over night that balance sheet can change into 50-100m worth in assets.

But hey keep reading raw paper work with no background knowledge seems to be working great for ur megalomaniac persona. Keep feeding urself in false hoods while living broke.

December 31 2023 total assets listed 33m liabilities same date 33m

https://www.otcmarkets.com/otcapi/company/financial-report/411734/content

Here’s the filling wear ur glasses it may help

"Talking about cybl"
I knew that and I was talking about CYBL when I posted. That should have been obvious from my response. .

You said that "They got 33m in assets also 33m in lability’s lol."
I'll ask again:
Are you reading that in CYBL's latest Balance Sheet as of 6/30/24 as filed with OTCMarkets? If so, you're reading it incorrectly. VERY incorrectly. Read it again or ask for help reading it.

I guess I need to ask this again, too:
Have you looked at RSPI's latest 10Q filing (as of 9/30/23)? Their Balance Sheet showed $108,664 in Assets and $12,405,118 in Liabilities. lol

Call me all the names you like but try to put together a cogent response.

I been slowly loading Ronn always gets pumped up from these levels. East wait and hold for 100-200 percent

Do u even own stock bro it’s funny how u are so cornered with us selling shares at cents of a dollar discount lmao

Damn bro I been in Sinc with a 0009 entry price been going through some turbulence but seems we are on track now

Nice, cant buy SINC from Europe, check AFFU. Bottom bouncer.

U see sinc late in 10 minutes...0013 and .002?

Need wait awhile! CEO won't talk about back to pink! Make holders piss

.0007 bid and .0013 bid get wack ...close 100% gain

Waiting for the day we trade Pink Current again.

Bid back .0007

Someone here learn lesson now...take advantage this time....last time he or she see and didnt wack it....

Liquidity just gushing like rapids on a river...

Wow 1.5M went off again.

The irony it was 20 bucks worth... lmao

Talking about cybl idiot

"They got 33m in assets also 33m in lability’s lol."

Are you reading that in their latest Balance Sheet as of 6/30/24 as filed with OTCMarkets? If so, you're reading it incorrectly. VERY incorrectly.

Have you looked at RSPI's latest 10Q filing (as of 9/30/23)? Their Balance Sheet showed $108,664 in Assets and $12,405,118 in Liabilities. lol

You're in a glass house Menace.

Stupid 20K brought us down again to 0.001

Charles won’t let me buy

They will settle around 003-004 then when convertible notes begin to cash in lol

They got 33m in assets also 33m in lability’s lol.

We would be trading at $0,064 with that market cap. It’s coming imo.

Up 6b shares is wild asf but hey if spzi can go to 02 with a similar share structure who’s to say about anything really lol

Yes there OS is 7 times higher, mkt cap 60M! That’s insanity.

We will go higher Idek what does cybl got even going for them? I couldn’t find anything substantial

CYBL lost CE and pushed from 0.002 to 0.012. Same will happen here.

Cyberlux Press Release Removal of CE and Elevation to Pink Current Status 10.08.2024